Rathbone Brothers plc Trims Holdings in Eli Lilly and Company (LLY)

Rathbone Brothers plc reduced its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 3.7% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 91,305 shares of the company’s stock after selling 3,521 shares during the period. Rathbone Brothers plc’s holdings in Eli Lilly and were worth $7,514,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the business. Vanguard Group Inc. increased its holdings in Eli Lilly and by 3.3% during the first quarter. Vanguard Group Inc. now owns 68,597,006 shares of the company’s stock valued at $5,769,694,000 after buying an additional 2,181,701 shares during the last quarter. BlackRock Inc. increased its holdings in Eli Lilly and by 2,628.5% during the first quarter. BlackRock Inc. now owns 62,260,488 shares of the company’s stock valued at $5,236,731,000 after buying an additional 59,978,664 shares during the last quarter. State Street Corp increased its holdings in Eli Lilly and by 1.6% during the first quarter. State Street Corp now owns 42,363,935 shares of the company’s stock valued at $3,563,230,000 after buying an additional 651,424 shares during the last quarter. Geode Capital Management LLC increased its holdings in Eli Lilly and by 8.4% during the first quarter. Geode Capital Management LLC now owns 9,103,975 shares of the company’s stock valued at $764,597,000 after buying an additional 708,597 shares during the last quarter. Finally, Janus Capital Management LLC increased its holdings in Eli Lilly and by 2.8% during the first quarter. Janus Capital Management LLC now owns 8,723,692 shares of the company’s stock valued at $733,731,000 after buying an additional 237,619 shares during the last quarter. 75.66% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “Rathbone Brothers plc Trims Holdings in Eli Lilly and Company (LLY)” was first published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at https://www.com-unik.info/2017/11/01/rathbone-brothers-plc-trims-holdings-in-eli-lilly-and-company-lly.html.

Eli Lilly and Company (LLY) opened at 81.94 on Wednesday. The company has a market cap of $86.45 billion, a price-to-earnings ratio of 35.46 and a beta of 0.34. The company’s 50 day moving average is $84.88 and its 200-day moving average is $82.19. Eli Lilly and Company has a 12 month low of $64.18 and a 12 month high of $89.09.

Eli Lilly and (NYSE:LLY) last issued its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 EPS for the quarter, topping the consensus estimate of $1.03 by $0.02. The company had revenue of $5.66 billion during the quarter, compared to analyst estimates of $5.52 billion. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.72%. The firm’s revenue was up 9.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.88 EPS. On average, analysts expect that Eli Lilly and Company will post $4.21 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, December 8th. Investors of record on Wednesday, November 15th will be issued a $0.52 dividend. This represents a $2.08 annualized dividend and a yield of 2.54%. The ex-dividend date of this dividend is Tuesday, November 14th. Eli Lilly and’s payout ratio is presently 98.58%.

In related news, major shareholder Lilly Endowment Inc sold 190,000 shares of the business’s stock in a transaction on Friday, September 15th. The shares were sold at an average price of $82.53, for a total value of $15,680,700.00. Following the completion of the sale, the insider now owns 123,682,287 shares of the company’s stock, valued at approximately $10,207,499,146.11. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In the last three months, insiders sold 770,000 shares of company stock valued at $64,669,850. 0.20% of the stock is owned by insiders.

A number of brokerages have commented on LLY. Morgan Stanley set a $86.00 target price on shares of Eli Lilly and and gave the company a “hold” rating in a report on Friday, October 6th. Leerink Swann increased their price objective on shares of Eli Lilly and from $92.00 to $93.00 and gave the stock a “market perform” rating in a research note on Monday, October 23rd. BMO Capital Markets set a $73.00 price objective on shares of Eli Lilly and and gave the stock a “sell” rating in a research note on Tuesday, October 24th. Credit Suisse Group cut shares of Eli Lilly and from an “outperform” rating to a “neutral” rating and increased their price objective for the stock from $84.23 to $88.00 in a research note on Tuesday, October 10th. Finally, Goldman Sachs Group, Inc. (The) reissued a “buy” rating and issued a $95.00 price objective (up from $92.00) on shares of Eli Lilly and in a research note on Thursday, October 5th. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $89.76.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

What are top analysts saying about Eli Lilly and Company? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Eli Lilly and Company and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit